|
Resolution: standard / high Figure 1.
The effects of high-mobility group box protein 1 (HMGB1) are dependent on complex
formation with different ligands. The figure depicts a possible, highly simplified
scenario for the mechanisms for the various functions of HMGB1. During initiation
of inflammation from infection, the abundant presence of Toll-like receptor (TLR)
ligands will induce signaling through TLR, resulting in strong, proinflammatory cytokine
production. The limited presence of HMGB1 at this stage will lead to weak signaling
through receptor for advanced glycation endproducts (RAGE), thereby inducing only
limited cell migration, proliferation, and differentiation. During the expansion phase
of inflammation, an increased concentration of HMGB1, released from both activated
and dead cells, occurs at the same time that TLR ligands are still present. Immune
complexes formed between HMGB1 and TLR ligands can induce signaling through RAGE and
TLR receptors in close proximity to each other. This signaling can increase and possibly
prolong cytokine production as well as enhance cell migration, proliferation, and
differentiation. During the regeneration/repair phase of inflammation, TLR ligands
decrease in amount while HMGB1 is still abundant. This situation will cause signaling
primarily through RAGE alone, leading to cell migration, proliferation, and differentiation
while cytokine production diminishes. The illustration above shows complex formation
between HMGB1 and TLR ligands. It is also possible that endogenous, non-TLR signaling,
danger molecules can form complexes with HMGB1 and affect HMGB1 function in a similar
way. HMGB1 can also enhance cytokine production when complexed to either lipopolysaccharide
or interleukin-1β. The scenario described for the regeneration and repair phase of
inflammation would also pertain to the function of HMGB1 during nerve sprouting, muscle
cell regeneration, and other non-inflammatory circumstances in which the presence
of HMGB1 has been described.
Pisetsky et al. Arthritis Research & Therapy 2008 10:209 doi:10.1186/ar2440 |